Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Hyperfine, Inc.✕ HYPR · #19,682 in the world |
|---|---|
| Profile | |
| Country | 🇺🇸 USA |
| Sector | Healthcare |
| Industry | Medical Devices |
| Founded | — |
| Size | |
| Market cap | $78 M |
| Revenue | $14 M |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Hyperfine, Inc. |
|---|---|
| 2025 | $14 MSEC |
| 2024 | $13 MSEC |
| 2023 | $11 MSEC |
| 2022 | $7 MSEC |
| 2021 | $2 MSEC |
| 2020 | $0 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $-36 M |
| Employees | 102 |
|---|
| Valuation | |
|---|---|
| Price to sales | 4.1× |
| Price to book | 1.9× |
| Free cash flow yield | -37.6% |
| Profitability | |
|---|---|
| Gross margin | 49.8% |
| Operating margin | -273.4% |
| Net margin | -262.3% |
| Return on equity | -79.0% |
| Growth | |
|---|---|
| Revenue growth | 5.2% |
| Revenue growth, 3 years a year | 25.8% |
| Financial strength | |
|---|---|
| Debt to equity | 0.0× |
| Cash | |
|---|---|
| Free cash flow margin | -214.8% |
| Altman Z-score zone | distress |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.